Revolution Medicines shares promising data around KRAS drug combination
Revolution Medicines has released promising Phase 1/2 clinical data for a KRAS drug combination targeting metastatic pancreatic cancer.
📍 How it ended
Revolution Medicines presented Phase 1/2 clinical data for Zoldonrasib combination regimens at the ESMO Gastrointestinal Cancers Congress 2026. The data focused on patients with RAS G12D metastatic pancreatic cancer and was described as promising.
Epilogue added 20d ago, after coverage quieted.
Coverage (5)
- Anirban Maitra։ Data on Zoldonrasib Plus Daraxonrasib in 2nd and 3rd Line Metastatic Pancreatic Cancer Oncodaily · 26d ago
- Practice-Changing Data in GI Oncology Medscape · 26d ago
- Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 Yahoo Finance · 26d ago
- Experimental cancer drug brings time and hope for patients WSAW · 26d ago
- Revolution Medicines shares promising data around KRAS drug combination Endpoints News · 26d ago
What happened
Revolution Medicines presented clinical data at the ESMO Gastrointestinal Cancers Congress 2026. The data concerns the use of Zoldonrasib combination regimens, specifically the pairing of Zoldonrasib and Daraxonrasib, for patients with RAS G12D metastatic pancreatic cancer in 2nd and 3rd line settings.
Coverage from Yahoo Finance, Endpoints News, and Oncodaily emphasizes the promising nature of the data. Medscape characterizes the findings as practice-changing for GI oncology, while WSAW reports that the experimental drug provides time and hope for patients.
Future developments involve the application of these combination regimens in metastatic pancreatic cancer treatment as the results from the Phase 1/2 trials are further analyzed.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 25d ago.
Questions people are asking
What specific drug combination was tested?
The combination consists of Zoldonrasib and Daraxonrasib.
Which patient group does this data target?
Patients with RAS G12D metastatic pancreatic cancer in 2nd and 3rd line settings.
Where was this data presented?
The findings were presented at the ESMO Gastrointestinal Cancers Congress 2026.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Topics
Related trends
A breakthrough in pancreatic cancer has experts excited
A new treatment for metastatic pancreatic cancer and KRAS-mutated cancers is generating optimism among experts and patients.
Pancreatic cancer breakthrough has big implications for early detection effort - San Diego Union-Tribune
An experimental pill called daraxonrasib is showing promising early results and gaining regulatory attention for treating pancreatic cancer.
Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
Roche's KRAS G12C inhibitor, divarasib, outperformed rival therapies in a head-to-head Phase 3 trial for lung cancer.
Grand Rapids oncologist says experimental pancreatic cancer drug showing promise in trials offers hope
An experimental drug for pancreatic cancer is generating hope among medical professionals and patients.